Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 9,990 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the transaction, the insider owned 254,388 shares in the company, valued at $1,793,435.40. The trade was a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Kaiser also recently made the following trade(s):

• On Monday, August 24th, Peter Kaiser sold 3,035 shares of Ocular Therapeutix stock. The shares were sold at an average price of $10.77, for a total value of $32,686.95.

Ocular Therapeutix Stock Performance

OCUL traded up $0.09 during midday trading on Tuesday, reaching $7.34. The company’s stock had a trading volume of 2,795,753 shares, compared to its average volume of 4,000,442. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14. The company has a fifty day simple moving average of $9.78 and a 200 day simple moving average of $9.28. The stock has a market cap of $1.61 billion, a P/E ratio of -5.17 and a beta of 1.00. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.20 million. During the same period in the previous year, the company earned ($0.39) earnings per share. The company’s quarterly revenue was down .1% compared to the same quarter last year. Research analysts expect that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current year.

Wall Street Analyst Weigh In

OCUL has been the subject of a number of research reports. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Chardan Capital restated a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a report on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Friday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.33.

Institutional Trading of Ocular Therapeutix

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Ocular Therapeutix during the 2nd quarter worth about $190,278,000. Commodore Capital LP acquired a new position in Ocular Therapeutix in the first quarter valued at about $21,810,000. Readystate Asset Management LP acquired a new position in Ocular Therapeutix in the first quarter valued at about $7,484,000. Defilade Capital Management L.P. grew its stake in Ocular Therapeutix by 118.2% during the first quarter. Defilade Capital Management L.P. now owns 1,487,645 shares of the biopharmaceutical company’s stock worth $12,600,000 after buying an additional 805,982 shares during the last quarter. Finally, Spruce Street Capital LP bought a new stake in Ocular Therapeutix during the fourth quarter worth about $9,518,000. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology.

Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional.